European Federation of Neurological Societies/Peripheral Nerve Society Guideline* on management of chronic inflammatory demyelinating polyradiculoneuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society

Richard A C Hughes, Pierre Bouche, David Cornblath, Eileen Evers, Robert D. Hadden, Angelika F. Hahn, Isabel Illa, Carol L. Koski, Jean Marc Léger, Eduardo Nobile-Orazio, John D. Pollard, Claudia Sommer, Peter Den Van Bergh, Pieter A. Van Doorn, Ivo N. Van Schaik

Research output: Contribution to journalArticle

Abstract

Background: Numerous sets of diagnostic criteria have sought to define chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), and randomized trials and systematic reviews of treatment have been published. Objectives: The aim of this guideline was to prepare consensus guidelines on the definition, investigation, and treatment of CIDP. Methods: Disease experts and a representative of patients considered references retrieved from MEDLINE and Cochrane Systematic Reviews in May 2004 and prepared statements that were agreed in an iterative fashion. Recommendations: The Task Force agreed on good practice points to define clinical and electrophysiological diagnostic criteria for CIDP with or without concomitant diseases and investigations to be considered. The principal treatment recommendations were as follows: (1) intravenous immunoglobulin (IVIg) or corticosteroids should be considered in sensory and motor CIDP (level B recommendation); (2) IVIg should be considered as the initial treatment in pure motor CIDP (good practice point); (3) if IVIg and corticosteroids are ineffective, plasma exchange should be considered (level A recommendation); (4) if the response is inadequate or the maintenance doses of the initial treatment are high, combination treatments or adding an immunosuppressant or immunomodulatory drug should be considered (good practice point); and (5) symptomatic treatment and multidisciplinary management should be considered (good practice point).

Original languageEnglish (US)
Pages (from-to)220-228
Number of pages9
JournalJournal of the Peripheral Nervous System
Volume10
Issue number3
DOIs
StatePublished - Sep 2005
Externally publishedYes

Fingerprint

Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Advisory Committees
Joints
Guidelines
Intravenous Immunoglobulins
Therapeutics
Adrenal Cortex Hormones
Patient Advocacy
Plasma Exchange
Immunosuppressive Agents
MEDLINE

Keywords

  • Chronic inflammatory demyelinating polyradiculoneuropathy
  • Definition
  • Diagnosis
  • Guidelines
  • Treatment

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

European Federation of Neurological Societies/Peripheral Nerve Society Guideline* on management of chronic inflammatory demyelinating polyradiculoneuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. / Hughes, Richard A C; Bouche, Pierre; Cornblath, David; Evers, Eileen; Hadden, Robert D.; Hahn, Angelika F.; Illa, Isabel; Koski, Carol L.; Léger, Jean Marc; Nobile-Orazio, Eduardo; Pollard, John D.; Sommer, Claudia; Van Bergh, Peter Den; Van Doorn, Pieter A.; Van Schaik, Ivo N.

In: Journal of the Peripheral Nervous System, Vol. 10, No. 3, 09.2005, p. 220-228.

Research output: Contribution to journalArticle

Hughes, Richard A C ; Bouche, Pierre ; Cornblath, David ; Evers, Eileen ; Hadden, Robert D. ; Hahn, Angelika F. ; Illa, Isabel ; Koski, Carol L. ; Léger, Jean Marc ; Nobile-Orazio, Eduardo ; Pollard, John D. ; Sommer, Claudia ; Van Bergh, Peter Den ; Van Doorn, Pieter A. ; Van Schaik, Ivo N. / European Federation of Neurological Societies/Peripheral Nerve Society Guideline* on management of chronic inflammatory demyelinating polyradiculoneuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. In: Journal of the Peripheral Nervous System. 2005 ; Vol. 10, No. 3. pp. 220-228.
@article{4eafc0dc35cb46ec9be835175610aea9,
title = "European Federation of Neurological Societies/Peripheral Nerve Society Guideline* on management of chronic inflammatory demyelinating polyradiculoneuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society",
abstract = "Background: Numerous sets of diagnostic criteria have sought to define chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), and randomized trials and systematic reviews of treatment have been published. Objectives: The aim of this guideline was to prepare consensus guidelines on the definition, investigation, and treatment of CIDP. Methods: Disease experts and a representative of patients considered references retrieved from MEDLINE and Cochrane Systematic Reviews in May 2004 and prepared statements that were agreed in an iterative fashion. Recommendations: The Task Force agreed on good practice points to define clinical and electrophysiological diagnostic criteria for CIDP with or without concomitant diseases and investigations to be considered. The principal treatment recommendations were as follows: (1) intravenous immunoglobulin (IVIg) or corticosteroids should be considered in sensory and motor CIDP (level B recommendation); (2) IVIg should be considered as the initial treatment in pure motor CIDP (good practice point); (3) if IVIg and corticosteroids are ineffective, plasma exchange should be considered (level A recommendation); (4) if the response is inadequate or the maintenance doses of the initial treatment are high, combination treatments or adding an immunosuppressant or immunomodulatory drug should be considered (good practice point); and (5) symptomatic treatment and multidisciplinary management should be considered (good practice point).",
keywords = "Chronic inflammatory demyelinating polyradiculoneuropathy, Definition, Diagnosis, Guidelines, Treatment",
author = "Hughes, {Richard A C} and Pierre Bouche and David Cornblath and Eileen Evers and Hadden, {Robert D.} and Hahn, {Angelika F.} and Isabel Illa and Koski, {Carol L.} and L{\'e}ger, {Jean Marc} and Eduardo Nobile-Orazio and Pollard, {John D.} and Claudia Sommer and {Van Bergh}, {Peter Den} and {Van Doorn}, {Pieter A.} and {Van Schaik}, {Ivo N.}",
year = "2005",
month = "9",
doi = "10.1111/j.1085-9489.2005.10302.x",
language = "English (US)",
volume = "10",
pages = "220--228",
journal = "Journal of the Peripheral Nervous System",
issn = "1085-9489",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - European Federation of Neurological Societies/Peripheral Nerve Society Guideline* on management of chronic inflammatory demyelinating polyradiculoneuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society

AU - Hughes, Richard A C

AU - Bouche, Pierre

AU - Cornblath, David

AU - Evers, Eileen

AU - Hadden, Robert D.

AU - Hahn, Angelika F.

AU - Illa, Isabel

AU - Koski, Carol L.

AU - Léger, Jean Marc

AU - Nobile-Orazio, Eduardo

AU - Pollard, John D.

AU - Sommer, Claudia

AU - Van Bergh, Peter Den

AU - Van Doorn, Pieter A.

AU - Van Schaik, Ivo N.

PY - 2005/9

Y1 - 2005/9

N2 - Background: Numerous sets of diagnostic criteria have sought to define chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), and randomized trials and systematic reviews of treatment have been published. Objectives: The aim of this guideline was to prepare consensus guidelines on the definition, investigation, and treatment of CIDP. Methods: Disease experts and a representative of patients considered references retrieved from MEDLINE and Cochrane Systematic Reviews in May 2004 and prepared statements that were agreed in an iterative fashion. Recommendations: The Task Force agreed on good practice points to define clinical and electrophysiological diagnostic criteria for CIDP with or without concomitant diseases and investigations to be considered. The principal treatment recommendations were as follows: (1) intravenous immunoglobulin (IVIg) or corticosteroids should be considered in sensory and motor CIDP (level B recommendation); (2) IVIg should be considered as the initial treatment in pure motor CIDP (good practice point); (3) if IVIg and corticosteroids are ineffective, plasma exchange should be considered (level A recommendation); (4) if the response is inadequate or the maintenance doses of the initial treatment are high, combination treatments or adding an immunosuppressant or immunomodulatory drug should be considered (good practice point); and (5) symptomatic treatment and multidisciplinary management should be considered (good practice point).

AB - Background: Numerous sets of diagnostic criteria have sought to define chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), and randomized trials and systematic reviews of treatment have been published. Objectives: The aim of this guideline was to prepare consensus guidelines on the definition, investigation, and treatment of CIDP. Methods: Disease experts and a representative of patients considered references retrieved from MEDLINE and Cochrane Systematic Reviews in May 2004 and prepared statements that were agreed in an iterative fashion. Recommendations: The Task Force agreed on good practice points to define clinical and electrophysiological diagnostic criteria for CIDP with or without concomitant diseases and investigations to be considered. The principal treatment recommendations were as follows: (1) intravenous immunoglobulin (IVIg) or corticosteroids should be considered in sensory and motor CIDP (level B recommendation); (2) IVIg should be considered as the initial treatment in pure motor CIDP (good practice point); (3) if IVIg and corticosteroids are ineffective, plasma exchange should be considered (level A recommendation); (4) if the response is inadequate or the maintenance doses of the initial treatment are high, combination treatments or adding an immunosuppressant or immunomodulatory drug should be considered (good practice point); and (5) symptomatic treatment and multidisciplinary management should be considered (good practice point).

KW - Chronic inflammatory demyelinating polyradiculoneuropathy

KW - Definition

KW - Diagnosis

KW - Guidelines

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=27644516384&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27644516384&partnerID=8YFLogxK

U2 - 10.1111/j.1085-9489.2005.10302.x

DO - 10.1111/j.1085-9489.2005.10302.x

M3 - Article

C2 - 16221283

AN - SCOPUS:27644516384

VL - 10

SP - 220

EP - 228

JO - Journal of the Peripheral Nervous System

JF - Journal of the Peripheral Nervous System

SN - 1085-9489

IS - 3

ER -